| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/20/2010 | EP2145628A1 Treatment of neurodegenerative disease through intracranial delivery of short interfering RNA (siRNA) |
| 01/20/2010 | EP2145627A1 Use of uridine in combination with choline for the treatment of memory disorders |
| 01/20/2010 | EP2145626A1 Combination Therapy for the Treatment of Cancer |
| 01/20/2010 | EP2145625A1 Cytidine derivative-containing antitumor agent for continuous intravenous administration |
| 01/20/2010 | EP2145624A1 Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment |
| 01/20/2010 | EP2145623A1 Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages |
| 01/20/2010 | EP2145622A1 Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors |
| 01/20/2010 | EP2145621A1 Prevention of dehydration and reduction of gluconeogenetic losses of amino acids by means of propane-1,2,3-triol |
| 01/20/2010 | EP2145620A2 Gaboxadol for treating depression and other affective disorders |
| 01/20/2010 | EP2145617A1 Gel formulation |
| 01/20/2010 | EP2145615A1 Skin-lightening agent containing equol compound as active ingredient |
| 01/20/2010 | EP2145192A1 Methods for measuring platelet reactivity of individuals treated with drug eluting stents |
| 01/20/2010 | EP2144921A2 Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
| 01/20/2010 | EP2144920A1 Novel compounds |
| 01/20/2010 | EP2144909A1 [2, 6]naphthyridines useful as protein kinase inhibitors |
| 01/20/2010 | EP2144908A1 2, 6-naphthyridine derivatives as protein kinase modulators |
| 01/20/2010 | EP2144905A1 Therapeutic agents |
| 01/20/2010 | EP2144904A1 (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent |
| 01/20/2010 | EP2144903A1 Substituted deuterium enriched thiophenes for the treatment of hypertension |
| 01/20/2010 | EP2144902A1 [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| 01/20/2010 | EP2144896A1 Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same |
| 01/20/2010 | EP2144893A2 Tricyclic compounds as matrix metalloproteinase inhibitors |
| 01/20/2010 | EP2144888A1 Methods for treating cancer |
| 01/20/2010 | EP2144887A1 Dosages and methods for the treatment of cancer |
| 01/20/2010 | EP2144886A1 Method of treating melanoma |
| 01/20/2010 | EP2144885A1 Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors |
| 01/20/2010 | EP2144883A1 Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine |
| 01/20/2010 | EP2144881A1 Isoquinolinone derivatives, processes for their preparation and their use in the treatment of chronic obstructive pulmonary disease ( copd ) and asthma |
| 01/20/2010 | EP2144877A1 Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof |
| 01/20/2010 | EP2144872A2 Low calcemic, highly antiproliferative, analogs of calcitriol |
| 01/20/2010 | EP2144871A1 Amidation process for the preparation of cathepsin k inhibitors |
| 01/20/2010 | EP2144870A2 Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
| 01/20/2010 | EP2144642A2 Implant material and method for treatment of urinary incontinence |
| 01/20/2010 | EP2144640A2 Reduction of infection associated with medical device |
| 01/20/2010 | EP2144618A1 Bioeffective krill oil compositions |
| 01/20/2010 | EP2144615A2 Methods of use of gamma inhibitor compounds for the attenuation of pain |
| 01/20/2010 | EP2144614A1 Methods for treating spinal muscular atrophy using tetracycline compounds |
| 01/20/2010 | EP2144613A2 Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| 01/20/2010 | EP2144612A2 Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| 01/20/2010 | EP2144611A1 Anti-tumor activity of temsirolimus in papillary renal cell cancer |
| 01/20/2010 | EP2144610A1 Melatonin tablet and methods of preparation and use |
| 01/20/2010 | EP2144609A2 Pharmaceutical formulations containing lipoic acid derivatives |
| 01/20/2010 | EP2144608A1 Sunscreen compositions and methods |
| 01/20/2010 | EP2144606A2 Remedy for the treatment of cardio-vascular diseases or disorders |
| 01/20/2010 | EP2144604A2 Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors |
| 01/20/2010 | EP2144603A1 Use of a monoterpene to treat or prevent stress |
| 01/20/2010 | EP2144599A2 Sustained release pellets comprising wax-like material |
| 01/20/2010 | EP2144597A1 Oil-in-water emulsions ii which are stabilized by their active ingredient |
| 01/20/2010 | EP2144590A1 Skin treatment compositions and methods |
| 01/20/2010 | EP2144507A1 Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques |
| 01/20/2010 | EP2144506A1 3-substituted-ý1,2,3¨-benzotriazinone compound for enhancing glutamatergic synaptic responses |
| 01/20/2010 | EP2144504A1 Method of treating brain cancer |
| 01/20/2010 | EP2144503A1 Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists |
| 01/20/2010 | EP2032123B1 Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
| 01/20/2010 | EP2003140B1 Galactose derivative, drug carrier and medicinal composition |
| 01/20/2010 | EP1991557B1 Mannosyl-1 phosphates, preparation method and therapeutic use, in particular against the cdg-ia syndrome |
| 01/20/2010 | EP1977246B1 Na+, k+-atpase expression in cervical dysplasia and cancer |
| 01/20/2010 | EP1968957B1 Substituted thiazoles and their use for producing drugs |
| 01/20/2010 | EP1963277B1 Fluorinated compounds |
| 01/20/2010 | EP1922420B1 METHOD AND SUBSTANCES FOR ISOLATING miRNAs |
| 01/20/2010 | EP1915387B1 Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use |
| 01/20/2010 | EP1828179B1 Nicotinic alpha-7 receptor ligands against cns-related diseases |
| 01/20/2010 | EP1828148B1 Triazole substituted aminobenzophenone compounds |
| 01/20/2010 | EP1827415B1 Cyclopropane acid derivatives for the reduction of lipid levels |
| 01/20/2010 | EP1824819B1 Pyrrolidin-2-one derivatives for use as dp1 receptor agonists |
| 01/20/2010 | EP1805141B1 Piperidines and related compounds for treatment of alzheimer's disease |
| 01/20/2010 | EP1758853B1 Glucagon receptor antagonists, preparation and therapeutic uses |
| 01/20/2010 | EP1675812B1 Bridged ring structures as pharmaceutical agents |
| 01/20/2010 | EP1663211B1 Aminotriazole compounds useful as inhibitors of protein kinases |
| 01/20/2010 | EP1663191B1 Composition comprising rosiglitazone and metformin |
| 01/20/2010 | EP1658064B1 Combinations of vasoactive agents, their use in the pharmaceutical and cosmetic field, and formulations containing them |
| 01/20/2010 | EP1654247B1 Alkynyl aryl carboxamides |
| 01/20/2010 | EP1648880B1 Therapeutic agents useful for treating pain |
| 01/20/2010 | EP1615647B1 Pharmaceutical use of fused 1,2,4-triazoles |
| 01/20/2010 | EP1611893B1 Remedy for nerve damage |
| 01/20/2010 | EP1608687B1 Novel cyclodextrin derivatives, method for the preparation thereof and use thereof for the solubilization of pharmacologically active substances |
| 01/20/2010 | EP1513818B1 Heterocyclic inhibitors of vegfr-2 kinases |
| 01/20/2010 | EP1506214B1 6-11 bicyclic ketolide derivatives |
| 01/20/2010 | EP1490333B1 New atorvastatin salts and pharmaceutical compositions containing them |
| 01/20/2010 | EP1474114B1 Oral dosage form for controlled drug release |
| 01/20/2010 | EP1458679B1 Pyrrolidine derivatives as prostaglandin modulators |
| 01/20/2010 | EP1456160B1 Vitamin d analogues |
| 01/20/2010 | EP1443970B1 Promoters exhibiting endothelial cell specificity and methods of using same |
| 01/20/2010 | EP1427396B1 Dosage forms having prolonged active ingredient release |
| 01/20/2010 | EP1418951B1 Transdermal therapeutic system (tts) with fentanyl as active ingredient |
| 01/20/2010 | EP1338603B1 Novel pyrazole derivatives and diabetes remedies containing the same |
| 01/20/2010 | EP1313422B1 Non-hormonal vaginal contraceptive |
| 01/20/2010 | EP1267880B2 Low dose entecavir formulation and use |
| 01/20/2010 | EP1218027B1 Composition for stabilizing corneal tissue during or after orthokeratological lens wear |
| 01/20/2010 | EP1204870B1 Method for determining physiological effects of hemoglobin |
| 01/20/2010 | EP1202961B1 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 01/20/2010 | EP1077994B1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same |
| 01/20/2010 | EP1059940B1 topical compositions comprising an alpha 1-adrenergic blocker FOR TREATING PAINFUL CONDITIONS OF THE ANAL REGION |
| 01/20/2010 | EP1028708B1 Topical compositions for prostaglandin e1 delivery |
| 01/20/2010 | EP0917538B1 Eukaryotic cells expressing at their surface at least an hla-g isoform and their applications |
| 01/20/2010 | CN201384713Y Piperazine ferulate enteric-coated tablet |
| 01/20/2010 | CN201384712Y Sodium ferulate enteric-coated tablet |
| 01/20/2010 | CN101631554A Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin |
| 01/20/2010 | CN101631553A Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications |
| 01/20/2010 | CN101631552A Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions |